Cowen & Co. analyst Steve Scala reiterated a Buy rating on Zoetis (NYSE: ZTS) yesterday and set a price target of $100. The company’s shares closed yesterday at $91.43, close to its 52-week high of $91.80.
According to TipRanks.com, Scala is a 4-star analyst with an average return of 7.1% and a 63.0% success rate. Scala covers the Healthcare sector, focusing on stocks such as GlaxoSmithKline, Eli Lilly & Co, and Bristol Myers.
Currently, the analyst consensus on Zoetis is a Moderate Buy with an average price target of $95.29, a 4.2% upside from current levels. In a report issued on July 30, Merrill Lynch also maintained a Buy rating on the stock with a $100 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $91.80 and a one-year low of $59.50. Currently, Zoetis has an average volume of 2.65M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Zoetis, Inc. discovers, develops and manufactures a portfolio of animal health medicines and vaccines. Its products are complemented by diagnostic products, genetic tests, bio devices and services.These are designed to meet the needs of veterinarians and the livestock farmers and companion animal.The firm provides its services though five categories namely, anti-infectives, vaccines, parasiticides, medicated feed additives, and other pharmaceuticals. The company was founded in July 2012 and is headquartered in New York, NY.
